J 2015

Unstable angina pectoris prior to ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention has no influence on prognosis

KLUZ, Krystyna, Jiří PAŘENICA, Lenka KUBKOVÁ, Simona LITTNEROVÁ, Josef TOMANDL et. al.

Basic information

Original name

Unstable angina pectoris prior to ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention has no influence on prognosis

Name in Czech

Nestabilní angina pectoris předcházející akutní infarkt myokardu s elevacemi ST-úseku u pacientů léčených pomocí primární PCI nemá vliv na prognózu

Authors

KLUZ, Krystyna (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Lenka KUBKOVÁ (203 Czech Republic, belonging to the institution), Simona LITTNEROVÁ (203 Czech Republic, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Martin POLOCZEK (203 Czech Republic, belonging to the institution), Ondřej TOMAN (203 Czech Republic, belonging to the institution), Martin TESÁK (203 Czech Republic, belonging to the institution), Zdeňka ČERMÁKOVÁ (203 Czech Republic, belonging to the institution), Jana GOTTWALDOVÁ (203 Czech Republic), Jan MAŇOUŠEK (203 Czech Republic), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution) and Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution)

Edition

Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic, Olomouc, Palacký University, 2015, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.924

RIV identification code

RIV/00216224:14110/15:00081975

Organization unit

Faculty of Medicine

UT WoS

000359128900014

Keywords (in Czech)

preinfarktová angina pectoris; STEMI; primární PCI; natriuretické peptidy

Keywords in English

pre-infarction angina pectoris; STEMI; primary PCI; natriuretic peptides

Tags

Tags

International impact, Reviewed
Změněno: 8/4/2016 09:14, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Background. Pre-infarction unstable angina pectoris (UAP) can be considered ischemic preconditioning. The aim of this study was to compare short and long term outcomes in patients with or without pre-infarction UAP and ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Methods. 593 patients with STEMI (388 without and 205 with UAP) were evaluated. Levels of biomarkers (troponin I, BNP, NT-ProBNP, neopterin, endoglin and pentraxin-3) at hospital admission and 24 h after STEMI onset were assessed. Echocardiography was undertaken on the fourth day after MI and after 12 months. The median follow-up was 37 months. Results. We found no significant differences in sex, age or risk factors for atherosclerosis between the UAP and non-UAP group. As the median time from the onset of chest pain to admission was significantly longer in the UAP group (228 min vs 258 min; P=0.009), we used a propensity score to obtain comparable matched groups for use in further analyses. The levels of NT-proBNP were significantly higher on admission and after 24 hours in the UAP group. Left ventricular functions according to invasive and echocardiographic parameters were entirely comparable at hospitalization and after 12 months. No differences were found in severity index of acute heart failure during hospitalization. The incidence of major acute coronary events during follow-up was comparable for the groups. Conclusions. In patients with STEMI treated with primary PCI, pre-infarction UAP has no beneficial clinical effect during hospitalization or during long-term follow-up.

Links

MUNI/A/0914/2012, interní kód MU
Name: Kritické zhodnocení využití nových biomarkerů NGAL, pentraxin 3 a quiescin Q6 v diagnostice a predikci prognózy u pacientů s akutním koronárním syndromem
Investor: Masaryk University, Category A